Form 4: Ekso Bionics Director, Li Kecheng, Reports Acquisition of Restricted Stock Units

Director Li Kecheng reports acquisition of 236,202 restricted stock units (RSUs) in Ekso Bionics Holdings, Inc.

Summary

• Li Kecheng, a director of Ekso Bionics Holdings, Inc., filed a Form 4 on May 19, 2025, reporting a transaction that occurred on May 16, 2025.
• The transaction involved the acquisition of 236,202 restricted stock units (RSUs).
• These RSUs were granted effective May 16, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, pursuant to an automatic annual non-employee director grant provision approved by the Company's Board of Directors on April 13, 2021.
• The RSUs are scheduled to vest and settle at the earlier of the date of the next Annual Meeting of Stockholders or the one-year anniversary of the Grant Date.
• Following the reported transaction, Li Kecheng beneficially owns 460,940 shares of common stock, including 236,202 unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard compensation practice. The acquisition of RSUs by a director is generally viewed positively, but it's a routine event.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future prospects.

Future Outlook

The RSUs are scheduled to vest and settle at the earlier of the date of the next Annual Meeting of Stockholders or the one-year anniversary of the Grant Date.

Industry Context

This filing is a routine disclosure related to director compensation and aligns with standard corporate governance practices.

Stakeholder Impact

• The RSU grant aligns director interests with shareholder value.

Key Dates

Keywords

EKSO, Ekso Bionics, Director, Li Kecheng, Form 4, Restricted Stock Units, RSUs, Beneficial Ownership, Securities